The Role of AI in Rare Disease Drug Discovery
AI, data-sharing, and gene technologies are peering into the future of rare disease drug development, and overcoming economic, regulatory, and diagnostic challenges for transformative therapies.
False
AI, data-sharing, and gene technologies are peering into the future of rare disease drug development, and overcoming economic, regulatory, and diagnostic challenges for transformative therapies.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
False
False
October 22, 2026
5 min read
Rob DiCicco discusses how FDA–industry collaboration is helping sponsors rethink safety reporting, selective safety data collection, and pragmatic clinical trial design.
October 22, 2026
5 min read
Alcami’s Kerrie Powell, Senior VP of Sales, discusses the challenges of sterile biologics manufacturing and what sponsors should look for in a CDMO partner
October 20, 2026
4 min read
Regeneron Genetics Center’s Luca Lotta explains how population-scale genetic evidence can reveal more promising drug targets and open new possibilities for disease prevention
October 20, 2026
5 min read
John Wichelt discusses Kindeva’s Bridgeton facility, supporting injectable programs from clinical development through commercial manufacturing, and choosing a long-term fill-finish partner
False
Affiliations:
Specialties:
Areas of Expertise: